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Abstract
Background: Over the last years, significant progress has been made in the comprehension of the molecular
mechanism of malaria resistance to drugs. Together with in vivo tests, the molecular monitoring is now part of the
survey strategy of the Plasmodium sensitivity. Currently, DNA-microarray analysis allows the simultaneous study
of many single nucleotide polymorphisms (SNP) of Plasmodium isolates. In December 2005, the International
Federation of the Red Cross distributed two million three hundred thousand long-lasting insecticide nets to
pregnant women and mothers of under five years children in the whole Niger. Then, Niger adopted artemisinin-
based combination therapy as first-line treatment.
Methods: Thirty four SNPs of pfcrt, pfdhfr, pfdhps, pfmdr and pfATPase were analysed by DNA-microarray and
PCR/RFLP in two villages – Zindarou and Banizoumbou – with different durations of malaria transmission. The
main objective of the study was to measure the dynamics of Plasmodium falciparum resistant strains and associated
factors.
Results: This study shows a global and clear increase of the drug-resistance associated molecular markers
frequencies during a relatively short-time period of four years. Markers associated with resistance to chloroquine
and sulphonamids were more frequently found in the short transmission zone than in the long transmission one.
The pfcrt76T mutation is significantly more present at Banizoumbou than Zindarou (38.3% vs 25.2%, p = 0.013).
This work allowed the screening of several field strains for five SNPs of PfATPase6 gene. The pfATPase6S769N,
candidate mutation of resistance to artemisinin was not found. However the pfATPsaeA623E mutation was found
in 4.7% of samples.
Conclusion: A significant increase of several SNPs frequencies was highlighted over a four-year period. The
polymorphism of five PfATPase6 gene SNPs was described. The global, large and fast increase of the molecular
resistance is discussed in the context of current changes of health policy and malaria control in Niger.
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Background
Malaria drug resistance is a major world wide public
health issue. If funding efficacious drugs is presently pos-
sible for many African countries, the future remains ques-
tionable. For many transmissible diseases, the efficacy of
chemical treatment is a matter of time and resistant strains
can emerge [1]. If regularly monitoring the pattern of drug
resistance is of prime importance, questioning the proc-
esses involved in the emergence of resistance and selec-
tion helps to define the treatment policy. Plasmodium
falciparum has been shown to use several mechanisms for
drug resistance. These last decades, the knowledge about
molecular mechanisms of malaria drug resistance has sig-
nificantly increased. Molecular surveys are now included
in the P. falciparum sensitivity surveillance strategy pro-
moted by the WHO, in association with in vivo tests. The
resistance to chloroquine is linked to the pfcrtK76T muta-
tion, a gene located on chromosome 7 [2], and clinical
assays have confirmed this association [3,4].
The dhfrS108N mutation, carried by chromosome 4, is the
key mutation site for resistance to pryrimethamine. How-
ever, the mutations of the SNPs 51 and 59 modulate it.
The triple mutation dhfrS108AN, dhfrC59R, dhfrN51I
have been shown to be selected in failures of the sul-
phadoxine-pyrimethamine association (SP) [5,6]. The
pfdhps gene on chromosome 8 is coding for the dihydrop-
teroate synthetase (pfdhps) and mutations of this gene are
linked to sulphamid resistance. The dhpsS436A,
dhpsA437G, dhpsK540E and dhpsA581G mutations have
been described [4,7]. The dhpsA437G, dhpsK540E double
mutation or the pfdhpsS436A, dhpsA437G, dhpsK540E tri-
ple mutation are found linked with the higher resistance
levels [5,7].
The multi-drug resistance gene of P. falciparum, localized
on chromosome 5, is coding for the P-glycoprotein. The
pfmdrA86Y mutation is suspected to be linked with the
cross-resistance to amodiaquine and chloroquine [8,9].
The copy number of pfmdr gene is suspected to be associ-
ated to mefloquine resistance [10]. The SERCA-pfATPase6
gene is a putative candidate to the artemisinin derivatives
resistance. The pfATPase6S769N mutation has been
described associated with artemether increased CI50 val-
ues in French Guyana [11]. However, this mechanism
does seem to be unique, since Plasmodium may develop
artemisinin resistance without that mutation [12].
Usually, the PCR-RFLP is used to study these mutations.
Even if robust and affordable for African malaria research
centres, this method does not allow a high throughput
screening of many mutations sites. The development of
micro-array techniques offers the ability of such a screen-
ing of many isolates [13], including field-collected ones
[14]. So the monitoring of P. falciparum sensitivity to treat-
ment survey can take benefit of this technique.
In Niger, malaria remains the main cause of morbidity
and mortality with about 850,000 declared cases a year,
an estimated incidence of 419/1,000 inhabitants and an
estimated global fatality rate of 0.56%[15], reaching 20%
in hospitalized patients [16].
However, Niger has entered in a very active phase of
malaria control. A mass distribution of long-lasting insec-
ticide-impregnated bed nets to mothers of children under
five has been implemented in December 2005. Pregnant
women benefit from intermittent preventive treatments
with sulphadoxine-pyrimethamine (SP). Finally, Niger
has adopted the use of artemisinin combination therapy
(ACT) as first-line treatment of uncomplicated malaria
cases. In this context, it is of prime importance to follow
the sensitivity of P. falciparum strains to treatment, both
old ones and new ones. Beside in vivo studies led by the
National Malaria Control Programme (PNLP) and WHO-
Niger [17], the CERMES has set up a molecular survey pro-
gramme [18]. Two molecular markers have been studied
by par PCR-RFLP: pfcrt76 and pfdhfr108. In the Niger river
valley, the prevalence of the pfcrt76T and dhfr108N muta-
tions was respectively 50.8% and 57% in 2005 [19]. In
collaboration with the Institute Pasteur of Cambodia,
some of the samples were tested with DNA-microarray
dedicated to the detection of Single Nucleotide Polymor-
phisms (SNPs) associated with P. falciparum resistance
[20,14].
To explore the conditions of emergence and spread, the
temporal evolution of molecular markers of P. falciparum
drug resistance was studied in two Sahel villages between
2003 and 2006. Usual old drugs-chloroquine and
pyrimethamine – were tracked by PfcrtK76T  and
pfdhfrS108N mutations by the microarray and PCR-RFLP
methods, while other potential molecular markers from
five genes, pfcrt, pfdhfr, pfdhps, pfmdr and pfATPase, were
studied only by the microarray technique.
Materials and methods
Study sites
Zindarou (13°26.09 N/2°55.23 E) and Banizoumbou
(13°32.03 N/2°39.66 E) are two villages of comparable
size (respectively 500 and 1,000 inhabitants), 70 km far
from Niamey and 20 km distant from each other (Figure
1). If the rainfall is considered to be equivalent, the land
use and topographies of the two villages determine differ-
ent length and intensities of malaria transmission. The
malaria transmission is short (three months) and strictly
linked to rainy season in Banizoumbou, while it goes
beyond five to six months in Zindarou with presence of
Anopheles funestus [21], in addition to Anopheles gambiae sl.Malaria Journal 2009, 8:32 http://www.malariajournal.com/content/8/1/32
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Study design
Samples from asymptomatic P. falciparum carriers were
tested from two villages (46 samples each). Patients were
stratified by age (under 15 and over 15 years old) and by
parasitaemia (46 patients presenting parasitaemia under
500 parasites and 46 over 500 parasites/μl). The two years
of collection, 2003 and 2006, were equally distributed (46
patients sampled in 2003 and 46 in 2006). The collections
were performed in October, at the end of the rainy sea-
sons. These samples were tested by DNA micro-array tech-
nique, targeting the global temporal evolution between
the two years 2003 and 2006 for five genes. These data
were completed by testing of additional samples from the
same two villages, respectively 250 and 245 samples in
Zindarou and Banizoumbou, collected during the four
years from 2003 to 2006. The aim of these extra materials
was to see if the temporal trend had a continuous or a dis-
continuous pattern. These last samples were tested by
PCR-RFLP for the only pfcrtK76T  and the pfdhfrS108N
mutations, which both presented the most evident tem-
poral evolutions by DNA micro-array technique. The
National Ethics Committee of Niger approved the study.
Methods
Blood slides and finger pricks on filter cards were per-
formed in the field. Parasite carriage was assessed by
Study sites Figure 1
Study sites. Map of Niger with the larger insert for the study zone showing the relative situation of villages to the Capital, 
Niamey. Scale bars for the Niger map.Malaria Journal 2009, 8:32 http://www.malariajournal.com/content/8/1/32
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microscopy after Giemsa staining. The parasitaemia
threshold was established to 40 parasites/μl. DNA was
extracted in 96 well-plates by resin method with Instagen.
Briefly, red blood cells were discarded from filter cards
after lysis with HBS1x/10% saponin (Hepes 100 mM,
NaCl 1.4 M, KCl 100 mM) buffer then washed three
times. Parasites were heated at 56°C then 90°C with
200μl of Instagen. Finally DNA was purified by centrifu-
gation at 4,000 rpm for 20 mn.
The PCR-RFLP methods targeting pfcrt76 and pfdhfr108
followed the procedures described by Djimdé et al [3] and
Kublin et al [5].
The microarray method was used as described in Crameri
et al [20]. This method was performed at the Institute Pas-
teur of Cambodia. A total of 34 SNPs from five different
genes (pfcrt, pfdhfr, pfdhps, pfmdr and pfATPase) were ana-
lysed by 34 SNPs. Decision values were determined by an
algorithm including absolute signal and relative (green/
red) values of optical densities [22]. Control samples with
known SNPs patterns were introduced in the assay.
Statistical analysis
The results were transferred to a database and analyzed by
EPI-Info™ (Centers for Disease Control and Prevention).
The mixed (wild + mutation) isolates were encoded as
mutation. The bivariate analysis was performed with Epi-
Info. Once found at p 0.20 significance threshold, the
independence of factors (age, sex, parasitaemia, village
and year) was tested by a conditional backward stepwise
logistical regression model with molecular markers as
dependant variables with the SPSS software (SPSS Inc.,
Chcago).
Results
Samples characteristics
495 samples were tested by PCR/RFLP, among which 250
from Zindarou and 245 from Banizoumbou villages. 92
samples were tested by DNA-chips method with 46 sam-
ples from each village. The mean age was 11.26 yrs old (N
= 587). The sex ratio (F/M) was 1.14 (N = 587). The mean
geometrical mean of parasitaemia was 1.364 parasites by
μl (N = 587).
Polymorphisms and prevalence of mutations
The data are presented gene by gene. The analysis was per-
formed on data following quality criteria, i.e. above opti-
cal density thresholds.
pfcrt gene
From the 12 SNPs used for the study of the pfcrt gene, two
did not give data for analysis (pfcrtQ271E  and
pfcrtN326S). Among the remaining 10 pfcrt  SNPs, five
(pfcrt72, pfcrt75, pfcrt152, pfcrt163, pfcrt356) did not show
any polymorphism and thefive others were polymorphic
at the 74, 76, 97, 220 and 371 codons (Table 1). All meth-
ods mixed, DNA micro-array and PCR/RFLP, the muta-
tion pfcrtK76T prevalence was 32.4%.
pfdhfr gene
Five SNPs targeted the pfdhfr  gene. Among them, one
(pfdhfrI164L) did not give sufficient quality for analysis
and another (pfdhfr16) was monomorphic. The three
remaining sites were polymorphic: pfdhfrS108N,
pfdhfrC59R and pfdhfrN51I with respective prevalences of
53.8%, 76.7% and 21.2%. The 51–59 double mutation
was present in 23.2% and the 51–59–108 triple mutation
in 11.8% of samples (Table 2).
pfdhps gene
Four SNPS presented polymorphisms in the pfdhps gene at
the 436, 437, 581 and 640 positions. The prevalence of
pfdhpsS436F, pfdhpsA437G double mutation was 61.2%.
The pfdhpsSer436Phe, pfdhpsA437G and pfdhpsA640T triple
mutation was present in 58.3% of cases and the
pfdhpsS436F,  pfdhpsA437G,  pfdhpsA581G,  pfdhpsA640Y
quadruple mutation in 10.6% (Table 3). The pfdhpsK540G
mutation was not found. No meaningful result was
obtained for the pfdhpsI613F codon. The codons dhps540
and dhps645 did not show any polymorphism.
Table 1: Relative frequencies of polymorphic Pfrct gene SNPs according to villages, ages and years
Number of samples Overall Banizoumbou vs Zindarou Adults vs under 15 2003 vs 2006
pfcrtMet74IIe 87 10.3% 11.1% vs 9.5%
(p = 1.0)
22.2% vs 7.1%
(p = 0.084)
0.0% vs 21.4%
(p = 0.001)*
pfcrtLys76Thr 318 32.4% 38.3%vs 25.2%
(p = 0.013)*
37.8% vs 31.5%
(p = 0.405)
20.0% vs 44.4%
(p = 0.013) *
pfcrtHis97gln 87 11.5% 15.6% vs 7.1%
(p = 0.317)
16.7% vs 10.1%
(p = 0.425)
2.2% vs 21.4%
(p = 0.006)
pfcrtAla220Ser 77 10.4% 10.0% vs 10.8%
(p = 1.0)
25.0% vs 6.5%
(p = 0.053)
0.0% vs 19.5%
(p = 0.006)*
in bold p < 0.05
* link kept in logistical regression model)
Global trend for samples from 2003 to 2006 years for pfcrt76 SNP geneMalaria Journal 2009, 8:32 http://www.malariajournal.com/content/8/1/32
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pfmdr gene
The two positions 86 (17.4%) and 1034 (4.6%) of the
pfmdr gene were polymorphic, but no double mutants was
found (Table 4). The codons pfmdrY184F  and
pfmdrN1246Y  did not give sufficient quality results to
allow the analysis. The pfmdr1042  position was found
monomorphic.
pfATPase6 gene
Only the 623 codon of the pfATPase6 gene was polymor-
phic and the mutation was found in 4.7% (4/86) of the
cases (Table 4). The pfATPaseS769N  mutation was not
found as were not the others targeted mutations at the
538, 574, and 683 codons.
Mutations associations
Only three strains presented both a mutation at pfmdr and
pfcrt genes (two with pfmdr86 and pfcrt76 and one with
pfmdr1034 and pfcrt76). All these three isolates came from
2006 samples.
Considering the pfdhfr and pfdhps genes, targeting the SP
efficacy, one strain presented both the triple 51, 59 and
108 pfdhfr mutation and the quadruple 436–437–581 and
640 pfdhps mutation. Among the triple pfdhfr mutants,
seven isolates presented at least one mutation at the pfdhps
gene; all of them were collected in 2006.
Variations according to time
All the five polymorphic codons of the pfcrt  gene pre-
sented a significantly increased prevalence between 2003
Table 2: Relative frequencies of polymorphic Pfdhfr gene SNPs according to villages, ages and years
Number of samples Overall Banizoumbou vs Zindarou Adults vs under 15 2003 vs 2006
pfdhfrAsn51IIe 85 21.2% 22.7% vs 19.5%
(p = 0.717)
23.5% vs 20.6%
(p = 0.75)
9.3% vs 33,3%
(p = 0.008)
pfdhfr Cys59Arg 56 76.7% 80.0% vs 73.1%
(p = 0.541)
77.8% vs 76.6%
(p = 0.939)
73.9% vs 78,8%
(p = 0.671)
pfdhfrSer108Ans 286 53.8% 58.4% vs 46.9%
(p = 0.057)
40.0% vs 56.1%
(p = 0.058)*
21.7% vs 45.7%
(p = 0.015)*
51,59 56 23.2% 20.0% vs 26.9%
(p = 0.541)
44.4% vs 19.1%
(p = 0.189)
4.3% vs 36.4%
(p = 0.008)*
51, 108 81 11.1% 12.2% vs 10.0%
(p = 1.0)
14.3% vs 10.4%
(p = 0.65)
4.7% vs 18.4%
(p = 0.076)
59,108 56 30.3% 40.0% vs 19.2%
(p = 0.092)
33.3% vs 29.8%
(p = 1.0)
7.4% vs 39.4%
(p = 0.139)
51, 59,108 56 11.8% 13.3% vs 11.5%
(p = 1.0)
22.2% vs 18.2%
(p = 0.312)
0% vs 21.2%
(p = 0.034)
in bold p < 0.05
* link kept in logistical regression model)
Samples from 2003 to 2006 years for pfdhfr108 SNP gene
Table 3: Relative frequencies of polymorphic Pfdhps gene SNPs according to villages, ages and years
Number of samples Overall Banizoumbou vs Zindarou Adults vs under 15 2003 vs 2006
pfdhpsSer436Phe 84 71.4% 73.8% vs 69.0%
(p = 0.629)
52.9% vs 76.1%
(p = 0.059)
76.2% vs 66.7%
(p = 0.334)
pfdhpsAla437Gly 49 73.4% 71.0% vs 77.8%
(p = 0.743)
50.0% vs 79.5%
(p = 0.06)
77.3% vs 70.4%
(p = 0.586)
pfdhpsAla581Gly 79 10.1% 19.0% vs 0.0%
(p = 0.006)*
12.5% vs 9.5%
(p = 0.661)
0.0% vs 20.5%
(p = 0.002)*
pfdhpsAla640Thr 90 97.8% 95.6% vs 100.0%
(p = 0.494)
100.0% vs 97.1%
(p = 1.0)
100.0% vs 95.5%
(p = 0.236)
436, 437 49 61.2% 61.3% vs 61.1%
(p = 0.99)
30.0% vs 69.2%
(p = 0.033)
68.2% vs 55.6%
(p = 0.367)
436, 437, 581 48 10.4% 16.1% vs 0.0%
(p = 0.146)
10.0% vs 10.5%
(p = 1.0)
0.0% vs 19.2%
(p = 0.054)
436, 437, 640 48 58.3% 56.7% vs 61.1%
(p = 0.762)
30.0% vs 65.8%
(p = 0.07)*
50.0% vs 68.2%
(p = 0.203)
436, 437,581, 640 47 10.6% 16.7% vs 0.0%
(p = 0.143)
10.0% vs 10.8%
(p = 1.0)
0.0% vs 20.0%
(p = 0.052)
in bold p < 0.05
* link kept in logistical regression modelMalaria Journal 2009, 8:32 http://www.malariajournal.com/content/8/1/32
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and 2006. For the pfcrt76T mutation, the year-to-year evo-
lution showed the same trend (Kruskall-Wallis df 3, p =
0.013) with the 2004/2005 transition statistically signifi-
cant (p < 0.05): 20% (2003), 27.8% (2004), 43.9%
(2005) and 41.8% (2006) (Figure 2).
For the pfdhfr gene, the mutations at positions 51 (p =
0.008) and 108 (p = 0.015) have also significantly an
increased prevalence between the two years 2003 and
2006. The prevalence of the pfdhfrS108N  mutation
increased significantly from year to year (Kruskall-Wallis df
3, p < 0.001) except between 2005 and 2006 where the
prevalence decreased significantly (p < 0.001). Between
2003 and 2006, the prevalence of the 51/59 double muta-
tion increased significantly from 4.3% to 36.4% (p =
0.008) as the 51/59/108 triple mutation from 0% to
21.2% (p = 0.034) (Table 2).
For the two pfdhps and pfmdr genes presenting respectively
four and two polymorphic codons, only the prevalences
of  pfdhpsA581G  (0% vs. 20.5%, p = 0.002) and
pfmdrS1034C (0% vs 9.8%, p = 0.048) mutations have sig-
Table 4: Relative frequencies of polymorphic Pfmdr and pfATPase genes SNPs according to villages, ages and years
Number of samples Overall Banizoumbou vs Zindarou Adults vs under 15 2003 vs 2006
pfmdrAsn86Ser 86 17.4% 13.6% vs 21.4%
(p = 0.341)
5.9% vs 20.3%
(p = 0.284)
22.7% vs 11.9%
(p = 0.186)
pfmdrSer1034Cys 86 4.6% 6.7% vs 2.4%
(p = 0.618)
12.5% vs 2.9%
(p = 0.156)
0.0% vs 9.8%
(p = 0.048)*
pfATPaseAla623Glu 86 4.7% 6.8% vs 2.4%
(p = 0.616)
5.6% vs 4.4%
(p = 1.0)
0.0% vs 9.5%
(p = 0.053)
in bold p < 0.05
* link kept in logistical regression model
Yearly evolution of pfcrt 76 (light grey) and pfdhfr 108 (dark grey) molecular markers Figure 2
Yearly evolution of pfcrt 76 (light grey) and pfdhfr 108 (dark grey) molecular markers. P coefficients correspond 
to chi-square two tailed tests.Malaria Journal 2009, 8:32 http://www.malariajournal.com/content/8/1/32
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nificantly increased between 2003 and 2006. All samples
with the pfATPaseAla623Glu mutation were found during
2006 (p = 0.053). Globally, among the all 15 polymor-
phic codons, the prevalence of nine were significantly
increasing between the 2003 and 2006 years, when no
mutation prevalence was significantly decreasing.
Variation according to the villages (malaria transmission 
length)
Globally, the pfcrt76T  mutation was significantly more
present at Banizoumbou than Zindarou (38.3% vs.
25.2%, p = 0.013) (Table 1). The other polymorphic
mutation positions (74, 97, 220 and 371) did not differ
between locations. For the pfdhfr gene, the 108 (58.4% vs.
46.9%), mutation and the 108/59 (40.0% vs. 19.2%)
double mutation had the same trend as pfcrt – i.e. higher
in Banizoumbou – but none significantly. For the pfdhps
gene, only the pfdhpsA581G mutation was significantly dif-
ferent in the two villages, being present only at Banizou-
mbou (19% vs. 0%, p = 0.006). The frequencies of
mutations of the two genes pfmdr and pfATPase were not
different in the two villages.
Variation according to host factor (age, sex, parasitaemia)
The only significant link found was the under 15 years age
more often associated with the double pfdhps 436–437
mutation (Table 3). No link was found between the stud-
ied mutations, parasitaemia or sex.
Discussion
The data show a global and significant increase of the drug
resistance associated molecular markers frequencies. This
increase concerns several (9 out of 15) polymorphic
molecular markers linked to different metabolic path-
ways. The study covered a relatively short-time period of
four years, showing a mean doubling of frequencies of
mutations highly linked to resistance, such as pfcrt76 and
pfhdfr108. The dynamics highlighted here appear to be
fast, global and intense.
These data add arguments to the debate about the links
between transmission and resistance [23,24]. On the one
hand, Talisuna et al in Uganda [24] have shown higher
levels of resistance to chloroquine and SP in zones of
higher transmission intensity. On the other hand, history
shows that chloroquine resistance emerged first in low
transmission zones and that antifolate resistance has
increased more rapidly in low transmission areas [25].
Theoretical models support the view that the spread of
resistance in low transmission area is favoured either by
the high selfing-rate [23] or by intra-host competition
[24]. Others models [26] have shown that the transmis-
sion rate may not be the main force driving the resistance
spread, which may rather be led by drug pressure or
immunity.
However, field data are scarce. Here, the mutations tended
to be more frequent in the village with the shorter malaria
season: Banizoumbou. This was verified for the pfcrtK76T
mutation. It has to be noted that the two villages share
very comparable social patterns (distance from main
road, health facilities, ethnicity, millet-based economy),
but differ in their water bodies – ie Anopheles breeding
sites – duration times. This corroborates the hypothesis
that the resistance could spread more easily in low-trans-
mission zones. The field data presented here correspond
to one of the most restricted spatial scale ever described
for this effect: these two villages are only 30 km distant.
History has shown at the worldwide-scale that resistance
emerged from low transmission area (Amazonia, South
East Asia), and this may be verified at a very local scale.
The same tendency for pfdhfr and others markers seems to
give a global value to the processes involved in the spread
of resistance.
The frequencies of mutation tended to be higher among
the younger parasite carriers. However, this relation was
significant only for the dhps436/437 double mutation. As
the immunity or the drug pressure may be involved, the
study was not designed to answer these issues. The global
prevalence of pfcrtK76T, 32.4%, was lower than in many
published works performed in Africa [27], but not so far
from regional data [3,28]. In comparison with local data
this prevalence was different from the one observed in
hospitalized urban population recorded in 2003: Ibrahim
et al found respective prevalence of pfcrtK76T  and
pfdhfrS108N mutations of 45.4% and 61.9% [18]. Later in
2005 [19] among patients attending rural health centres,
the prevalence was closer to the 2005 values: 50.8% for
pfcrt76 and 57.7% for dhfr108. However, the present work
was targeting asymptomatic carriers in a rural zone, not
patients attending to clinics or hospitals, and the drug
pressure appears to be different in those different popula-
tions.
Recent works have studied the ATPase6 gene and specially
the pfATPase6S769N mutation as a candidate marker for
artemisinin resistance [11]. For first time, several field
strains could be screened for five SNPs of PfATPase6 gene.
The pfATPase6S769N mutation was not found. However,
the pfATPaseA623E mutation was found in 4.7% of sam-
ples. The more precise sequence data for this gene are pre-
sented elsewhere [29].
The respective factors driving the emergence and spread of
malaria drug resistance are not well known. Drug pres-
sure, clonality of infections, pharmacokinetics, human
migrations, immunity, fitness of parasites and transmis-
sion levels have all been suspected [24-27,30,31]. One
interesting point of this work is the role of the interven-
tion to block transmission. Two millions and three hun-Malaria Journal 2009, 8:32 http://www.malariajournal.com/content/8/1/32
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dred thousands long-lasting insecticide-impregnated bed
nets were distributed in December 2005. The bed nets
reduce the lifespan of the vectors and the contact between
human host and vector. This decreases the malaria trans-
mission. Alifrangis et al have observed a significant
decrease of molecular resistance to pryrimethamine after
impregnated bed nets in Tanzania [32]. On the other
hand, a controled trial of the impact of impregnated bed
nets in Ivory Coast found no significant difference in pfcrt,
pfdhfr and pfdhps mutations prevalences between treated
villages and negative controls [33,34]. Diallo et al in
Burkina Faso observed that impregnated curtains are not
associated with an increase of molecular resistance or
therapeutic failure in children under five years of age [35].
A decrease or stabilization of the molecular resistance has
been shown between 2005 and 2006 for pfcrtK76T and
pfdhfrS108N  (Figure 2), when the trend is to a global
increase during the 2003–2006 period. During this
period, given the parasite carriage among children
between two and five years of age, the malaria transmis-
sion in the two villages has decreased significantly (chi-
square p < 0.0001), whether due or not to the impreg-
nated bed nets distribution, from 56.5% (n = 255) in
2005 to 37.1% (n = 237) in 2006. What was observed in
molecular markers then could be related either to a
decrease of drug pressure or to a direct effect of transmis-
sion decrease on mutation carrying strains. A decrease of
drug pressure cannot account for the pfdhfrS108N dynam-
ics, when the SP is not often used in the study zone and
rarely as the first-line treatment [18]. Beside this drug
pressure hypothesis, the decrease of resistant strains may
be related to:
￿ An absolute – i.e. in absence of drug pressure – weaker
fitness of resistant strains in competition with wild strains
during the transmission season: this is compatible with
the observed higher frequency of resistant strains in low
transmission area, where the competition between strains
related to the chance of transmission events, is lower.
￿ A best fitness of mutation carrying strains, when drugs
are delivered during the malaria season, with a relative
lower fitness of wild strains, especially at the end of the
transmission season when the drug pressure is maxima.
This effect is cumulative during the dry season, when there
is no transmission and thus no competition with wild
strains. So the resistance could favour the longer parasite
carriage during the dry season, but not the competition
with wild strains as the new transmission season begins.
This theoretical view is in accordance of the observed
decrease after bed net distribution by personal protection
and decrease of drug pressure.
￿ Whatever the processes involved, and taking in account
the short duration time of the malaria transmission
period in Sahel, the selective advantage kept all along the
dry season by mutation carrying strains seems to be cumu-
lative from year to year and tends to a global increase.
Conclusion
This work highlights a global increase of frequencies of
mutation molecular markers linked to malaria drug resist-
ance during a relatively short period of four years. Given
the wide range of molecular markers studied by the DNA
microarray method, the observed increase of several
markers corresponds to different metabolic pathways.
This reinforces the hypothesis of a global process involv-
ing transmission and fitness of mutation, rather than
simultaneous drug pressures. In the context of new rein-
forcement of malaria control in Niger, based both on
introduction of artemisinin-based combination therapy
and vector control, the present data may be considered as
baseline data for future drug resistance monitoring.
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